Evidence map›Paper›PMID 40603433›Full record

ArticleScientific reports2025

Chiral pyrimidinyl-piperazine carboxamide derivatives as potent yeast α-glucosidase inhibitors.

Noval Herfindo, Pirun Mikled, Neni Frimayanti, Thanyada Rungrotmongkol, Warinthorn Chavasiri

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Noval HerfindoDepartment of Chemistry, Faculty of Science, Center of Excellence in Natural Products Chemistry, Chulalongkorn University, Pathum Wan, Bangkok, 10330, Thailand.
Pirun MikledProgram in Biotechnology, Faculty of Science, Chulalongkorn University, Pathum Wan, Bangkok, 10330, Thailand.
Neni FrimayantiSekolah Tinggi Ilmu Farmasi (STIFAR), Pekanbaru, Riau, 28293, Indonesia.
Thanyada RungrotmongkolCenter of Excellence in Biocatalyst and Sustainable Biotechnology, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok, 10330, Thailand.
Warinthorn ChavasiriDepartment of Chemistry, Faculty of Science, Center of Excellence in Natural Products Chemistry, Chulalongkorn University, Pathum Wan, Bangkok, 10330, Thailand. warinthorn.c@chula.ac.th.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

α-Glucosidase is an important target in treating type 2 diabetes, and thus, the inhibition of this enzyme could delay sugar digestion and avoid postprandial hyperglycemia. Previous studies revealed that some pyrimidine and piperazine derivatives showed good affinity towards α-glucosidase. In continuing efforts toward the development of α-glucosidase inhibitor, a series of pyrimidinyl-piperazine carboxamide 6-22 containing chiral center have been synthesized. The inhibition activity was evaluated against α-glucosidase from Saccharomyces cerevisiae. All tested compounds exhibit excellent inhibition effects compared to acarbose (IC

Indexed as

alpha-GlucosidasesGlycoside Hydrolase InhibitorsPiperazinesPyrimidinesSaccharomyces cerevisiaeKineticsMolecular Docking SimulationMolecular Dynamics SimulationPiperazineStructure-Activity Relationshipalpha-GlucosidasesGlycoside Hydrolase InhibitorsPiperazinePiperazinesPyrimidines

Identifiers

PMID40603433
PMCPMC12222516

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.